[1]柳卫,张满达,王铁生.钠/碘同向转运体[J].国际放射医学核医学杂志,2001,25(2):49-52.
　LIU Wei.The sodium/iodide symporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(2):49-52.
点击复制

钠/碘同向转运体(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
25
期数:
2001年第2期
页码:
49-52
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
The sodium/iodide symporter
作者:
柳卫;  张满达;  王铁生
214063 江苏无锡, 核医学国家重点实验室
Author(s):
LIU Wei
State key laboratory of nuclear medicine, Jiangsu Wuxi 214063, China
关键词:
钠/碘同向转运体; 放射性碘治疗
Keywords:
sodium/iodide symporter; radioactive iodide therapy
分类号:
R581.023;R817.8
摘要:
钠/碘同向转运体是甲状腺滤泡细胞基底细胞膜上的糖蛋白,介导甲状腺对碘的主动运输。本文综述钠/碘同向转运体在基因、蛋白质二级结构、电生理学特征、调控及组织分布等方面的进展,及其对甲状腺疾病和放射性碘治疗的意义。
Abstract:
The sodium/iodide symporter (NIS), an integral plasma membrane glycoprotein of the basolateral membrane of the thyroid gland follicular cells, mediates the active transport of iodide into thyroid cells. In this review, the main accomplishments of the study of NIS at molecular level were concisely described, including the NIS gene, the secondary structure and electrophysiological character of NIS protein, and their regulation and tissue distribution. The impacts of NIS on thyroid disease and radioactive iodide therapy were also evaluated.

参考文献/References:

[1] Dai G,Levy O,Carrasco N.Cloning and characterization of the thyroid iodide transporter[J].Nature,1996,379:458-460.
[2] Smanik PA,Liu Q,Furminger TL,et al.Cloning of the human sodium iodide symporter[J].Biochem Biophys Res Commun,1996,226:339-345.
[3] Levy O,Vieja A,Ginter CS,et al.N-linked glycosylation of the thyroid Na+/I- symporter (NIS)[J].J Biol Chem,1998,273:22657-22663.
[4] Smanik PA,Ryu KY,Theil KS,et al.Expression,exon-intron,organization,and mapping of the human sodium iodide symporter[J].Endocrinology,1997,138:3555-3558.
[5] Eskandari S,Loo DDF,Dai G,et al.Thyroid Na+/I- symporter mechanism stoicchiometry and specificity[J].J Biol Chem,1997,272:27230-27238.
[6] Yoshida A,Sasaki N,Mori A,et al.Different electro physiological character of I-,ClO4-,and SCN- in the transport by Na+/I- symporter[J].Biochem Biophys Res Commun,1997,231:731-734.
[7] Caillou B,Troalen F,Baudin E,et al.Na+/I- symporter distribution in human thyroid tissues:an immunohistochemical study[J].J Clin Endocrinol Metab,1998,83:4102-4106.
[8] DeleuS,Allory Y,Radulescu A,et al.Characterization of autonomous thyroid adenoma:metabolism gene expression,and pathology[J].Thyroid,2000,10:131-140.
[9] Arturi F,Russo D,Schlumberger M,et al.Iodide sympoter gene expression in human thyroid tumors[J].J Clin Endocrinol Metab,1998,83:2493-2496.
[10] Varyre L,Sabourin JC,Caillou B,et al.Immunohistochemical analysis of Na+/I- symporter distribution in human extra-thyroid tissues[J].Eur J Endocrinol,1999,141:382-386.
[11] Ajjan RA,Kamaruddin NA,Crisp M,et al.Regulation and tissue distribution of the human sodium iodide symporter gene[J].Clin Endocrinol Oxf,1998,49:517-523.
[12] Spitzweg C,Joba W,Eisenmenger W,et al.Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acid from salivary gland,mammary gland,and gastric mucosa[J].J Clin Endocrinol Metab,1998,83:1746-1751.
[13] Kogai T,Endo T,Saito T,et al.Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells[J].Endocrinology,1997,138:2227-2232.
[14] Saito T,Endo T,Kawaguchi A,et al.Increased expression of the sodium/iodide symporter in cultured human thyroid cells exposed to thyrotropin and in Graves’ thyroid tissue[J].J Clin Endocrinol Metab,1997,82:3331-3336.
[15] Trapasso F,Iuliano R,Chiefari E,et al.Iodide symporter gene expression in normal and transformed rat thyroid cells[J].Eur J Endocrinol,1999,140:447-451.
[16] Pekary AE,Hershman JM.Tumor necrosis factor,ceramide,transforming growth factor-betal,and aging reduce Na+/I- symporter messenger ribonucleic acid levels in FRTL-5 cells[J].Endocrinology,1998,139:703-712.
[17] Suzuki K,Mori A,Saito J,et al.Follicular thyroglobulin suppresses iodide uptake by suppressing expression of the sodium/iodide symporter gene[J].Endocrinology,1999,140:5422-5430.
[18] Ajjan RA,Watson PF,Findlay C,et al.The sodium iodide symporter gene and its regulation by cytokines found in autoimmunity[J].J Endocrinol,1998,158:351-358.
[19] Eng PH,Cardona GR,Fang SL,et al.Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein[J].Endocrinology,1999,140:3404-3410.
[20] Uyttersprot N,Pelgrims N,Carrasco N,et al.Moderate doses of iodide in vivo inhibit cell proliferation and the expression of thyroperoxidase and Na+/I- symporter mRN As in dog thyroid[J].Mol Cell Endocrinol,1997,131:195-203.
[21] Endo T,Kaneshige M,Nakazato M,et al.Thyroid transcription factor-1 activates the promoter activity of rat thyroid Na+/I- symporter gene[J].Mol Endocrinol,1997,11:1747-1755.
[22] Ohmori M,Endo T,Harri N,et al.A novel thyroid transcription factor is essential for thyrotropin-induced up-regulation of Na+/I- symporter gene expression[J].Mol Endocrinol,1998,12:727-736.
[23] Ohno M,Zannini M,Levy O,et al.The paired-domain transcription factor pax 8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-speciflc and cyclic-AMP-dependent transcription[J].Mol Cell Biol,1999,19:2051-2060.
[24] Benvenga S,Bartolone L,Trimarchi F.Thyroid iodide transporter;local sequence homologies with thyroid autoantigens[J].J Endocrinol Invest,1997,20:508-512.
[25] Mori JC,Bergert ER,Bryant WP.Binding of immunoglobulin G from patients with autoimmune thyroid disease to rat sodium:iodide symporter peptides:evidence for the iodide transporter as a autoantigen[J].Thyroid,1997,7:527-534.
[26] Ajjan RA,Findlay C,Metcalfe RA,et al.The modulation of the human sodium iodide symporter activity by Graves’ disease sera[J].J Clin Endocrinol Metab,1998,83:1217-1221.
[27] Matsuda A,Kosugi S.A homozygous missense mutation of the sodium/iodide symporter gene causing iodide transporter defect[J].J Clin Endocrinol Metab,1997,82:3966-3971.
[28] Wang W,Macapinlac H,Larson SM,et al.[18F]-2-fluoro-deoxy-d-dlucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels[J].J Clin Endocrinol Metab,1999,84:2291-2302.
[29] Schmutzler C,Winzer R,Meissner WJ,et al.Reti-noic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in non transformed FRTL-5 rat thyroid cells[J].Biochem Biophys Res Commun,1998,246:562-568.
[30] Schmutzler C,Winzer R,Weigl JM,et al.Retinoic acid-a potential bifunctional therapeutic tool for treating thyroid carcinomas[J].Exp Clin Endocrinol Diabetes,1998,106(Suppl 1):s3.
[31] Grunwald F,Menzel C,Bender H,et al.Redifferentiation therapy-induced radioiodine uptake in thyroid cancer[J].J Nucl Med,1998,39:1903-1906.
[32] Mandelell RB,Mendlell LZ,Link CJ Jr.Radioisotope concentrator gene therapy using the sodium/iodide symporter gene[J].Cancer Res,1999,59:661-668.
[33] Spitzweg C,Zhang S,Bergert ER,et al.Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines[J].Cancer Res,1999,59:2136-2141

相似文献/References:

[1]欧阳萌.131I治疗儿童及青少年Graves病[J].国际放射医学核医学杂志,2004,28(2):70.
　OU Yang-meng.131I therapy of Graves’ disease in childhood and adolescence[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(2):70.
[2]张一帆,李彪.钠/碘同向转运体在甲状腺癌131I治疗中的应用[J].国际放射医学核医学杂志,2004,28(6):249.
　ZHANG Yi-fan,LI Biao.Application of sodium/iodide symporter gene in thyroid cancer for radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(2):249.
[3]李倩.钠/碘转运体的临床实用价值[J].国际放射医学核医学杂志,2003,27(2):56.
　LI Qian.Clinical value of sodium iodide symporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(2):56.
[4]葛素娟.甲状腺癌术后131I治疗[J].国际放射医学核医学杂志,2002,26(4):163.
　GE Su-juan.131I therapy of thyroid cancer after surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(2):163.
[5]邢岩.TPO基因及其应用研究[J].国际放射医学核医学杂志,2002,26(6):248.
　XING Yan.The research and application of TPO’s gene[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(2):248.
[6]罗全勇.基因转染诱导核素靶向治疗的实验研究[J].国际放射医学核医学杂志,2001,25(2):60.
　LUO Quan-yong.Inducement of radionuclides targeting therapy by gene transfection[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(2):60.
[7]丁昊,叶斌,雷勇.增强DTC病灶摄取131I功能的措施[J].国际放射医学核医学杂志,2001,25(4):145.
　DING Hao,YIE Bin,LEI Yong.The augmentation of 131I uptake of DTC[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(2):145.
[8]黄蕤.NIS基因转染肿瘤细胞介导131I治疗[J].国际放射医学核医学杂志,2001,25(5):204.
　HUANG Rui.Transfection of the Na+/I- symporter gene into tumors for radioiodide therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(2):204.
[9]陈立波.钠/碘同向转运体与放射性碘治疗[J].国际放射医学核医学杂志,2001,25(6):258.
　CHEN Li-bo.The sodium/iodide symporter and radioiodide therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(2):258.

备注/Memo

备注/Memo:
收稿日期:2000/9/25。
作者简介:柳卫(1971-),男,江苏南京人,南京医科大学第一附属医院核医学科讲师,复旦大学医学院硕士研究生,现在核医学国家重点实验室主要从事甲状腺疾病研究。
更新日期/Last Update: 1900-01-01